Wealthfront Advisers LLC Catalent, Inc. Transaction History

Wealthfront Advisers LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 01, 2023	BUY	$44.2 - $50.2 $279,786 - $317,766	6,330 New	6,330 $288,000
Q1 2023 Apr 28, 2023	BUY	$45.44 - $74.26 $48,666 - $79,532	1,071 Added 16.11%	7,721 $507,000
Q4 2022 Feb 10, 2023	BUY	$41.39 - $81.0 $136,338 - $266,814	3,294 Added 98.15%	6,650 $299,000
Q3 2022 Nov 14, 2022	SELL	$72.36 - $113.1 $314,693 - $491,871	-4,349 Reduced 56.44%	3,356 $243,000
Q2 2022 Jul 20, 2022	BUY	$87.2 - $114.05 $48,396 - $63,297	555 Added 7.76%	7,705 $827,000
Q1 2022 May 16, 2022	BUY	$94.19 - $124.49 $46,812 - $61,871	497 Added 7.47%	7,150 $793,000
Q4 2021 Jan 21, 2022	BUY	$119.57 - $139.07 $2,630 - $3,059	22 Added 0.33%	6,653 $852,000
Q3 2021 Nov 15, 2021	BUY	$109.17 - $142.35 $10,152 - $13,238	93 Added 1.42%	6,631 $882,000
Q2 2021 Aug 16, 2021	SELL	$100.34 - $115.69 $416,912 - $480,691	-4,155 Reduced 38.86%	6,538 $707,000
Q1 2021 May 14, 2021	BUY	$101.51 - $125.27 $319,553 - $394,349	3,148 Added 41.72%	10,693 $1.13 Million
Q4 2020 Feb 16, 2021	BUY	$85.88 - $105.36 $420,983 - $516,474	4,902 Added 185.47%	7,545 $785,000
Q3 2020 Nov 16, 2020	BUY	$72.74 - $92.5 $192,251 - $244,477	2,643 New	2,643 $226,000

514

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11.4B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Wealthfront Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Wealthfront Advisers LLC with notifications on news.